Literature DB >> 24613576

Differences of 25-hydroxyvitamin D3 concentrations in children and adults with neurofibromatosis type 1.

Claudia Schnabel1, Stefan Dahm2, Thomas Streichert3, Wulf Thierfelder2, Lan Kluwe4, Victor F Mautner4.   

Abstract

OBJECTIVES: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder, frequently associated with reduced bone mineral density. Serum 25-hydroxyvitamin D3 concentrations in NF1 adults are lower than in healthy controls in autumn respectively winter and are inversely correlated with the number of dermal neurofibromas. We investigated 25-hydroxyvitamin D3 levels in children and adults with neurofibromatosis type 1 in winter and summer and compared them to healthy controls to get more pathogenic insights in vitamin D3 metabolism in NF1 patients. DESIGN AND METHODS: NF1 patients were clinically examined and serum 25-hydroxyvitamin D3 concentrations were measured in 58 NF1 adults and 46 children in winter as well as in summer and compared to sex-, age- and month-matched controls.
RESULTS: 52 adults suffered from 10 to 5000 dermal neurofibromas, whereas none of the children presented neurofibromas. 25-Hydroxyvitamin D3 increased from winter to summer (mean: 21.0 to 46.5nmol/l) in NF1 adults. This increase was even larger (p=0.0001) than in healthy controls (mean: 50.5 to 60.5nmol/l). However, there were no differences of 25-hydroxyvitamin D3 concentrations in NF1 children and healthy controls both in winter and in summer.
CONCLUSIONS: Only adults with NF1 showed lower 25-hydroxyvitamin D3 levels in winter and summer, which are unlikely due to impaired UV-dependent dermal synthesis, but rather might be caused by an accelerated catabolism.
Copyright © 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neurofibromatosis type 1; Vitamin D3 deficiency

Mesh:

Substances:

Year:  2014        PMID: 24613576     DOI: 10.1016/j.clinbiochem.2014.02.020

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  5 in total

1.  Bone Status According to Neurofibromatosis Type 1 Phenotype: A Descriptive Study of 60 Women in France.

Authors:  Maud Jalabert; Salah Ferkal; Jean-Claude Souberbielle; Emilie Sbidian; Arthur Mageau; Florent Eymard; Philippe Le Corvoisier; Laurence Allanore; Xavier Chevalier; Pierre Wolkenstein; Sandra Guignard
Journal:  Calcif Tissue Int       Date:  2021-02-08       Impact factor: 4.333

2.  Age-dependent oral manifestations of neurofibromatosis type 1: a case-control study.

Authors:  Eshwar Thota; John Jims Veeravalli; Sai Krishna Manchala; Bhargavi Priya Lakkepuram; Jayasurya Kodapaneni; Yi-Wen Chen; Li-Tzu Wang; Kevin Sheng-Kai Ma
Journal:  Orphanet J Rare Dis       Date:  2022-03-02       Impact factor: 4.123

Review 3.  The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective.

Authors:  Amish Chinoy; Grace R Vassallo; Emma Burkitt Wright; Judith Eelloo; Siobhan West; Eileen Hupton; Paula Galloway; Amy Pilkington; Raja Padidela; M Zulf Mughal
Journal:  J Musculoskelet Neuronal Interact       Date:  2022-03-01       Impact factor: 1.864

4.  Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age Group.

Authors:  Alessandra Santos; Mauro Geller; Spyros Mezitis; Allan E Rubenstein; Lisa Oliveira; Daniel Jm Medeiros Lima; Mendel Suchmacher Neto; Rafael Nigri; Karin Gonçalves Soares Cunha; Sanyu Takirambudde; Marcia Gonçalves Ribeiro
Journal:  Clin Pathol       Date:  2020-10-19

Review 5.  Current Aspects on the Pathophysiology of Bone Metabolic Defects during Progression of Scoliosis in Neurofibromatosis Type 1.

Authors:  Angelos Kaspiris; Olga D Savvidou; Elias S Vasiliadis; Argyris C Hadjimichael; Dimitra Melissaridou; Stella Iliopoulou-Kosmadaki; Ilias D Iliopoulos; Evangelia Papadimitriou; Efstathios Chronopoulos
Journal:  J Clin Med       Date:  2022-01-15       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.